NAPM rebrands as Generic and Biosimilar Medicines Southern Africa

Herman Grobler, chairman of GBM, and Vivian Frittelli, CEO of GBM, revealing the new branding and logo for Generic and Biosimilar Medicines Southern AfricaThe National Association of Pharmaceutical Manufacturers (NAPM) revealed its new branding and name change to Generic and Biosimilar Medicines Southern Africa (GBM) on 11 May. The association – which was launched 40 years ago – continues to keep pace with global industry developments.

According to Cipla’s Herman Grobler, chairman of GBM (newly branded NAPM), the pharmaceutical industry has developed and changed substantially over the years. ‘While manufacturing in South Africa hasn’t kept pace, and the NAPM has continued to change its focus from manufacturing and supply to also addressing the needs of patients and their access to affordable and quality medicines,’ he comments.  

Part of a global movement

Over the past two years, various international pharma industry associations representing the interests of manufacturers of generic medicines have changed their names and strategic focus to incorporate biosimilars. The NAPM is now following suite with its rebranding.

Revealing the GBM’s new logo at a conference which took place at Blue Valley Hills Estate in Midrand, Gauteng, Grobler says the logo is made up of various elements. ‘The outstretched arms welcome like-minded pharmaceutical companies aligned with association’s ethos. The leaves illustrate the GBM’s aim for safe, affordable and efficacious medicines for patients in South and southern Africa.’ 

Growth in generic ultilisationGavin Steel, chief director at National Department of Health, addressing delegates at the launch of Generic and Biosimilar Medicines Southern Africa

In South Africa, generic medicines have allowed our country to have the most robust and accessible HIV programme in the world.

According to Madeleine Bester from Mediscor, there has been good increase in generic utilisation in South Africa over the past nine years. ‘The industry is making great advances as a result of increased availability. The treatment of HIV/Aids remains a success area in the use of generic meds with 73.9 percent of medicines used in 2015 for HIV/Aids treatment being generic,’ says Bester.

She congratulated the NAPM on its rebranding stressing the importance of biosimilars in driving down costs and increasing patient access to necessary treatment. ‘Biological entities are very expensive,’ comments Bester, ‘the average cost per patient is around R70 000 per year, sparking a definite demand for biosimilars to curb the exorbitant costs associated with treating illnesses like cancers.’

Dr Roshini Moodley Naidoo from Discovery Health also congratulated the NAPM on the move to realign its focus as the GBM. ‘Biosimilars are a key part of the journey in driving access to affordable care,’ she comments. ‘As a result, Discovery is eagerly awaiting the registration of more biosimilars from the MCC.’

‘One in four people in South Africa consumes ARVs – the NAPM has played a key role in driving this access to much needed generic medicines,’ says Gavin Steel, chief director at National Department of Health. He believes the GBM is going to take health care in South Africa into the next era.

Steel also shared some of the successes achieved with generic medicines over the past 15 years. ‘We’ve seen a 71 to 88 percent price reduction in hypertension medicine from 2003 to now. This is thanks to the significant access initiatives driven by the NAPM,’ he comments. ‘South Africa now has the lowest priced ARVs in the world as a result of voluntary licensing and the use of generic medicines.’

An exciting new chapter

The GBM is the successor to the NAPM and represents the interests of generic and biosimilar medicine manufacturers and marketers in South Africa. The association’s mission is to champion greater access to medicine by the South African population.

Vivian Frittelli, CEO of GBM (newly rebranded NAPM) says that an exciting development in South Africa is Cipla’s establishment of a biosimilar plant at the Dube Trade Port near Durban. On completion, this plant will be able to provide more affordable life-saving treatments where biological drugs are required.

‘The Medicines Control Council has approved a registration guideline for biosimilar medicines in South Africa and are based on international best practices,’ says Frittelli. ‘The cost-efficiencies, which generic and biosimilar medicines provide, are going to assume greater importance for state and private health funders as populations age and the prevalence of cancers and other non-communicable diseases increases.’

The GBM will use its new corporate identity to not only help develop and commercialise biomedical technologies in South Africa, but also to provide a greater understanding of these kinds of emerging health care technologies. ‘It represents an exciting new chapter in the growth and development of our association,’ Frittelli concludes.  



Latest


18 Jan 2021
Solvay commits to sustainable cyclopentanone production

Solvay has begun a process of decarbonising the cyclopentanone unit of its Melle plant in France. Through an agreement with…

Solvay commits to sustainable cyclopentanone production

Solvay has begun a process of decarbonising the cyclopentanone unit of its Melle plant in France. Through an agreement with an agricultural cooperative for the next 15 years, the entire cyclopentanone production will indeed rely solely on biomethane gas, a green source of energy. The cooperative built a facility to…

18 Jan 2021
Irene Cantos becomes IMCD’s group director Personal Care

IMCD has appointed Irene Cantos as business group director Personal Care, effective 6 January 2021. In her role, Cantos, will…

Irene Cantos becomes IMCD’s group director Personal Care

IMCD has appointed Irene Cantos as business group director Personal Care, effective 6 January 2021. In her role, Cantos, will lead the Business Group Personal Care in becoming the global player of choice for both suppliers and customers in the distribution of speciality ingredients. The group aims to grow both…

15 Jan 2021
IDC awards major financing facility to Teqal

Based in KwaZulu-Natal, Teqal is a specialist producer of biodegradable injection moulded rigid plastic packaging for cosmetics and industrial products.…

IDC awards major financing facility to Teqal

Based in KwaZulu-Natal, Teqal is a specialist producer of biodegradable injection moulded rigid plastic packaging for cosmetics and industrial products. In December, the company was awarded a R50mn financing facility by the IDC to expand its factory. Globally plastic waste accounted for 6.3bn metric tons in 2015. This amount of…

14 Jan 2021
BASF founds coalition to build a circular economy in the self adhesive labelling industry

BASF is a founding member of a new global network dedicated to building a circular economy in the self-adhesive labelling…

BASF founds coalition to build a circular economy in the self adhesive labelling industry

BASF is a founding member of a new global network dedicated to building a circular economy in the self-adhesive labelling industry. CELAB (Toward a Circular Economy for Labels) is a cross-industry coalition open to all companies in the self-adhesive label supply chain, promoting sustainability through encouraging collaboration, kick- starting regional…


Top stories


25 Jun 2020
How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a…

How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a changing environment, whether it be internal or external. Qualities of agile businesses include being adaptive, flexible and creative in your response to change without losing momentum (remaining productive) or vision.…

01 May 2020
Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex,…

Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex, which continuously invests in technological advancements to meet requirements in diverse industries – has increased production capacity of materials so desperately needed during the global COVID-19 pandemic,” explains Rosa Naidoo,…

23 Apr 2020
Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love.…

Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love. Santam, Fairlady and, for the first time this year, Truelove Magazine, have partnered up in the search to find the best female entrepreneurs in the country. Best women entrepreneurs If…

30 Nov 2017
Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form…

Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form of diabetes, known as “type 3” diabetes and Alzheimer’s disease.


Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za